Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05194735 |
Title表达 T 细胞受体 (TCR) 的自体 T 细胞对实体瘤受试者的 I/II 期研究 | 阶段
第 1 阶段
|
Date Added 2022-01-18 |
地点
Texas, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product |
标签
MSS/ MMRp
|
| NCT ID NCT05722327 |
TitlePhase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2023-02-10 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, Irinotecan, MRTX849 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03772561 |
TitleAZD5363 + Olaparib + Durvalumab 治疗晚期或转移性实体瘤恶性肿瘤患者的 I 期研究 | 阶段
第 1 阶段
|
Date Added 2018-12-11 |
地点
新加坡
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
AZD5363+Olaparib+Durvalumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06105021 |
TitlePhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | 阶段
Phase 1, Phase 2
|
Date Added 2023-10-27 |
地点
California, United States
Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
AFNT-211 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06302062 |
TitlePhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2024-03-08 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04793958 |
TitleKRAS G12C突变晚期结直肠癌患者MRTX849联合西妥昔单抗与化疗的3期研究（KRYSTAL-10） | 阶段
第三阶段
|
Date Added 2021-03-11 |
地点
Alabama, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States 阿根廷 澳大利亚 Austria 比利时 巴西 加拿大 中国 Colombia Czechia 丹麦 Finland 法国 德国 希腊 香港 Ireland 意大利 大韩民国 Malaysia 墨西哥 荷兰 波兰 葡萄牙 波多黎各 Romania 新加坡 西班牙 台湾 泰国 Ukraine 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06589440 |
TitlePhase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | 阶段
第二阶段
|
Date Added 2024-09-19 |
地点
New Jersey, United States
Texas, United States Washington, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Balstilimab, Botensilimab |
标签
MSS/ MMRp
|
| NCT ID NCT05480306 |
TitlePhase 2 Study of DKN-01 in Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-07-29 |
地点
Arizona, United States
California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States 德国 大韩民国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, DKN-01, FOLFIRI, FOLFOX |
标签
MSS/ MMRp
|
| NCT ID NCT06039202 |
TitleCA102N 联合 TAS-102 与贝伐珠单抗联合 TAS-102 治疗复发性和/或难治性转移性结直肠癌受试者的 2 期研究比较 | 阶段
第二阶段
|
Date Added 2023-09-15 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
CA102N, TAS-102 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04046445 |
Title对 IV 期结直肠癌患者进行 ATP128、VSV-GP128 和 BI 754091 评估的 1b 期研究 | 阶段
第 1 阶段
|
Date Added 2019-08-06 |
地点
Arizona, United States
California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States 比利时 德国 瑞士 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
ATP128, BI 754091, VSV-GP128 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
